
Invivyd Inc (IVVD) Stock Forecast & Price Target
Invivyd Inc (IVVD) Analyst Ratings
Bulls say
Invivyd is well positioned to thrive in the biopharmaceutical industry with their successful development of PEMGARDA and their promising pipeline of antibody candidates for various viral diseases. They have a clear goal of improving quality of life for patients and a diverse portfolio that mitigates risks. Furthermore, their partnerships and focus on new variants showcase their ability to adapt to changing market conditions and remain competitive. While there are risks in the industry, Invivyd's track record and potential for future growth make it a strong investment opportunity with positive long-term prospects.
Bears say
Invivyd is heavily dependent on the success of its lead product PEMGARDA, approved for the prevention of COVID-19 in immunocompromised individuals. However, the next-generation antibody VYD2311 in its pipeline is not significantly different from PEMGARDA and may face stiff competition in the already crowded COVID-19 prophylaxis market. Additionally, the company's commercialization and regulatory risks should not be overlooked, as a large marketing partner may be needed for commercial success and the FDA's acceptance of immuno-bridging data for approval may not be guaranteed. The company's flu program shows potential but is not a significant contributor to its current valuation, leaving most of the stock's upside dependent on the success of its COVID-19 antibodies.
This aggregate rating is based on analysts' research of Invivyd Inc and is not a guaranteed prediction by Public.com or investment advice.
Invivyd Inc (IVVD) Analyst Forecast & Price Prediction
Start investing in Invivyd Inc (IVVD)
Order type
Buy in
Order amount
Est. shares
0 shares